News
SVRA
5.87
-3.29%
-0.20
Savara publishes corporate presentation highlighting MOLBREEVI program in autoimmune PAP
PUBT · 8h ago
Savara says FDA extended review for Molgramostim BLA
TipRanks · 8h ago
Savara Announces FDA Extends Review Period For Molgramostim Inhalation Solution Biologics License Application In Autoimmune Pulmonary Alveolar Proteinosis
Benzinga · 8h ago
FDA extends Savara molgramostim BLA review, pushing PDUFA date to Nov. 22, 2026
PUBT · 8h ago
SAVARA INC - FDA EXTENDS REVIEW PERIOD FOR MOLGRAMOSTIM BLA IN AUTOIMMUNE PAP BY THREE MONTHS
Reuters · 8h ago
Savara presents new Phase 3 IMPALA-2 molgramostim data at ATS 2026
PUBT · 1d ago
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
Barchart · 1d ago
Weekly Report: what happened at SVRA last week (0406-0410)?
Weekly Report · 2d ago
Savara (SVRA) Is Up 6.5% After Multi-Region Accelerated Reviews Granted for MOLBREEVI Therapy
Simply Wall St · 6d ago
Assessing Savara (SVRA) Valuation After Accelerated Review Progress For MOLBREEVI
Simply Wall St · 04/08 00:28
BUZZ-U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
Reuters · 04/07 15:40
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
TipRanks · 04/07 14:35
BUZZ-U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara
Reuters · 04/07 13:08
BUZZ-Savara rises as UK accepts application for rare lung disease drug
Reuters · 04/07 12:46
Savara publishes corporate presentation highlighting MOLBREEVI autoimmune PAP Phase 3 data
Reuters · 04/07 12:19
Savara's MOLBREEVI MAA Accepted By MHRA For Autoimmune PAP, Joining Ongoing FDA And EMA Reviews With Decisions Expected Across U.S., EU, And U.K. Within 12 Months
Benzinga · 04/07 12:13
Savara announces MHRA accepted submission of Molbreevi MAA
TipRanks · 04/07 12:11
Savara says UK MHRA accepts Molbreevi filing for autoimmune PAP under accelerated review
Reuters · 04/07 12:05
SAVARA INC - CHMP DECISION ON MOLBREEVI MAA EXPECTED IN Q1 2027
Reuters · 04/07 12:05
Weekly Report: what happened at SVRA last week (0330-0403)?
Weekly Report · 04/06 09:22
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.